Lycera Corporation

Plymouth, MI, United States

Lycera Corporation

Plymouth, MI, United States

Time filter

Source Type

The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR) and provides adoptive cellular therapies using an agonist of ROR, populations of lymphocyte cells that have been exposed to an agonist of ROR, populations of dendritic cells that have been exposed to an agonist of ROR, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR to a patient.


The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.


The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.


The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F_(1)F_(0)-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.


The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F_(1)F_(0)-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.


The invention provides pyrazolyl guanidine compounds that inhibit F_(1)F_(0)-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.


The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR) and provides adoptive cellular therapies using an agonist of ROR, populations of lymphocyte cells that have been exposed to an agonist of ROR, populations of dendritic cells that have been exposed to an agonist of ROR, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR to a patient.


The invention provides pyridonyl guanidine compounds that inhibit F_(1)F_(0)-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.


The invention provides pyrazolyl guanidine compounds that inhibit F_(1)F_(o)-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.


The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

Loading Lycera Corporation collaborators
Loading Lycera Corporation collaborators